Abstract
The first family identified as having a nonsyndromic intellectual disability was mapped in 1988. Here we show that a mutation of IQSEC2, encoding a guanine nucleotide exchange factor for the ADP-ribosylation factor family of small GTPases, caused this disorder. In addition to MRX1, IQSEC2 mutations were identified in three other families with X-linked intellectual disability. This discovery was made possible by systematic and unbiased X chromosome exome resequencing.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
IQSEC2 mutation associated with epilepsy, intellectual disability, and autism results in hyperexcitability of patient-derived neurons and deficient synaptic transmission
Molecular Psychiatry Open Access 17 September 2021
-
Pharmacological modulation of AMPA receptors rescues specific impairments in social behavior associated with the A350V Iqsec2 mutation
Translational Psychiatry Open Access 22 April 2021
-
Structural and functional brain-wide alterations in A350V Iqsec2 mutant mice displaying autistic-like behavior
Translational Psychiatry Open Access 22 March 2021
Access options
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Mulley, J.C. et al. Am. J. Med. Genet. 43, 383–391 (1992).
Turner, G. et al. Dev. Med. Child Neurol. 13, 71–78 (1971).
Suthers, G.K., Turner, G. & Mulley, J.C. Am. J. Med. Genet. 30, 485–491 (1988).
Gecz, J., Shoubridge, C. & Corbett, M. Trends Genet. 25, 308–316 (2009).
Tarpey, P.S. et al. Nat. Genet. 41, 535–543 (2009).
Murphy, J.A. et al. Brain Res. 1120, 35–45 (2006).
Sakagami, H. et al. Neurosci. Res. 60, 199–212 (2008).
Beraud-Dufour, S. et al. EMBO J. 17, 3651–3659 (1998).
Puertollano, R. et al. Cell 105, 93–102 (2001).
Farnsworth, C.L. et al. Nature 376, 524–527 (1995).
Munshi, H.G. et al. Biochem. 35, 15883–15889 (1996).
Morleo, M. et al. Mol. Med. Rep. 1, 33–39 (2008).
Casanova, J.E. Traffic 8, 1476–1485 (2007).
Ramocki, M.B. & Zoghbi, H.Y. Nature 455, 912–918 (2008).
Dölen, G. et al. Neuron 56, 955–962 (2007).
Acknowledgements
We would like to express our gratitude to the participating individuals and families and to N. Briggs for assistance with statistical analysis. The work has been supported by the Australian National Health and Medical Research Council to J.G., the SMILE Foundation, the Women's and Children's Hospital Foundation, D. Harwood, US National Institutes of Health (HD26202) to C.E.S., the South Carolina Department of Disabilities and Special Needs (SCDDSN), the Medical Research Council (S.R. and R.J.H.), Action Medical Research and the Wellcome Trust for support under grant reference 077012/Z/05/Z.
Author information
Authors and Affiliations
Contributions
C.S., M.S., F.A., A.G. and J.B. assembled the extended families and confirmed, tracked and analyzed the changes. A.P., H.P. and M.S. performed additional subject and control screening. P.S.T., A.F. and M.R.S. supervised the X-chromosome sequencing, collation and analysis of the sequencing data. A.H., M.F., R.E.S., G.T., C.E.S. and F.L.R. contributed families and clinical data on affected individuals. C.S., S.L.R., J.A.M., R.S.W., R.J.H. and S.R. performed functional assays. C.S. and J.G. conceived and designed the study and wrote the first draft of the manuscript. J.G. directed the study. All authors contributed to discussion of the results and manuscript preparation.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Note, Supplementary Figures 1 and 2 and Supplementary Tables 1 and 2 (PDF 958 kb)
Rights and permissions
About this article
Cite this article
Shoubridge, C., Tarpey, P., Abidi, F. et al. Mutations in the guanine nucleotide exchange factor gene IQSEC2 cause nonsyndromic intellectual disability. Nat Genet 42, 486–488 (2010). https://doi.org/10.1038/ng.588
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.588
This article is cited by
-
IQSEC2 mutation associated with epilepsy, intellectual disability, and autism results in hyperexcitability of patient-derived neurons and deficient synaptic transmission
Molecular Psychiatry (2021)
-
Structural and functional brain-wide alterations in A350V Iqsec2 mutant mice displaying autistic-like behavior
Translational Psychiatry (2021)
-
Pharmacological modulation of AMPA receptors rescues specific impairments in social behavior associated with the A350V Iqsec2 mutation
Translational Psychiatry (2021)
-
Novel familial IQSEC2 pathogenic sequence variant associated with neurodevelopmental disorders and epilepsy
neurogenetics (2020)
-
Incorrect dosage of IQSEC2, a known intellectual disability and epilepsy gene, disrupts dendritic spine morphogenesis
Translational Psychiatry (2017)
